Tyra Biosciences Inc. Common Stock (TYRA)

FairStock Score: 23/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings, modest debt, and a price that leaves a margin of safety. Tyra Biosciences does not yet fit that template. It is a clinical-stage biotechnology company developing FGFR-targeted precision medicines through its SNÅP platform, with a lead FGFR3 candidate in trials, and 87 employees. The filed figures show no revenue. Net losses have deepened: fiscal 2023 net loss was $69.1 million, fiscal 2024 was $86.5 million, and fiscal 2025 was $119.9 million. In fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $39.3 million, or $0.64 per diluted share; in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $45.6 million, or $0.69 per diluted share. Trailing free cash flow is negative $109.9 million, giving a FairStock FCF yield of -9.9% based on the $18.56 close on 2026-10-13. The balance sheet has low leverage, with a D/E of 0.02 and an Altman Z-Score of 21.78 per FairStock, but that does not remove the need to fund continuing losses. FairStock also shows a negative P/E of -7.77, P/B of 3.13, ROE of -45.31%, ROCE of -28.46%, and a Piotroski F-Score of 0/9. Its FairStock Score is 23/100, and it has no Lynch category because it has lost money each of the last four years. Without revenue or profits, the $1.1 billion market cap is a wager on clinical success, not a Graham-style bargain. I would need evidence of trial validation, controlled cash burn, and a clear path to revenue before calling this a business rather than an option.

In plain English: Tyra Biosciences is a small research-stage drug developer with 87 employees. It is trying to make precision medicines for cancer and other conditions, but it has no reported sales and has lost money every year as it pays for research and trials. At the $18.56 close on 2026-10-13, the $1.1 billion market value rests on future hope rather than current profits, so based on today's numbers it looks speculative rather than cheap or fairly valued.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer